Alemtuzumab: phase III results


The results of the phase III trials, CARE MS-I and CARE MS-II, show that alemtuzumab significantly reduces relapse rate by about 50% compared to interferon-beta-1a SC (Cohen et al. Lancet 2012; 380:1819-1828).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page